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Natural Killer (NK) cells are innate lymphocytes with an important role in the early defense
against intracellular pathogens and against tumors. Like other immune cells, almost
every aspects of their biology are regulated by cytokines. Interleukin (IL)-15 is pivotal for
their development, homeostasis, and activation. Moreover, numerous other activating or
inhibitory cytokines such as IL-2, IL-4, IL-7, IL-10, IL-12, IL-18, IL-21, Transforming growth
factor-β (TGFβ) and type I interferons regulate their activation and their effector functions at
different stages of the immune response. In this review we summarize the current under-
standing on the effect of these different cytokines on NK cell development, homeostasis,
and functions during steady-state or upon infection by different pathogens. We try to delin-
eate the cellular sources of these cytokines, the intracellular pathways they trigger and
the transcription factors they regulate. We describe the known synergies or antagonisms
between different cytokines and highlight outstanding questions in this field of investiga-
tion. Finally, we discuss how a better knowledge of cytokine action on NK cells could help
improve strategies to manipulate NK cells in different clinical situations.
Keywords: natural killer cells, cytotoxicity, interferons, signal transduction, interleukin-15, interleukin-12,
interleukin-18,TGF-beta
Natural killer (NK) cells are Innate Lymphoid Cells (ILC) involved
in the immuno-surveillance of cancers and in the early control of
infections by intracellular pathogens (1). They can kill cells rec-
ognized as targets through a battery of surface receptors (2) and
produce large amounts of IFN-γ upon activation (1). Recently, the
growing ILC family has been reclassified into three groups accord-
ing to the pattern of cytokine they secrete. In this classification, NK
cells are part of the group 1 ILC subset (3). In mice, NK cells mainly
develop in the bone marrow (BM) (4, 5). If the earliest commit-
ted NK cell progenitor (pre-pro NK) does not express CD122 (6)
which is the β subunit of the IL-2/IL-15 receptor, expression of
this molecule is acquired soon after at the NK precursor (NKP)
stage (7). The expression of this receptor is thereafter conserved
and is a hallmark of the NK cell population. This underlines the
fact that the various aspects of NK cell development, homeostasis,
and function are conditioned by IL-15. If this cytokine is funda-
mental, a variety of other cytokines have been shown to influence
the behavior of NK cells, alone or in synergy. In this review, we aim
to describe the complex interplay between the molecular pathways
triggered by these cytokines. We restricted our field of investiga-
tion to the direct effects of cytokines on NK cells. We believe that
a good understanding of these pathways is essential to the rational
design of drugs targeting the various aspects of NK cell functions.
THE γc FAMILY OF CYTOKINES
The central role of cytokines sharing the γc subunit as a
co-receptor (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21) in the
constitution of the NK cell pool was appreciated some 20 years ago.
Indeed, X-linked severe combined immunodeficiency patients
presenting mutations leading to loss of γc function (8) and mice
with targeted γc deletion (9) both presented a quasi absence
of NK cells indicating that these cells relied on one or more
of these cytokines. Absence of mature NK cells in mice genet-
ically deficient in IL-2/15Rβ chain restricted the list of candi-
dates to IL-2 and IL-15 (10). Finally, genetic ablation of IL-
15 (11) or IL-15Rα (12), leading to a very similar phenotype
with a near complete absence of mature NK cells, formally
demonstrated the paramount importance of this cytokine for
the generation of NK cells. In contrast, mice deficient for IL-
2, IL-4, and IL-7 had normal NK cell numbers under home-
ostatic conditions (13). Importantly and despite expression of
IL-2/15Rβ, NKPs appeared to be independent of γc signaling
since they were present in normal numbers in γc deficient ani-
mals, suggesting that IL-15 only becomes important for sub-
sequent maturation steps (13). Other γc cytokines are also
involved in NK cell homeostasis and activation as summarized
in Figure 1.
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FIGURE 1 | γc Cytokines regulate NK cell homeostasis and function.
Different cytokines use γc as a co-receptor to regulate NK cell biology.
The cellular source of these cytokines is indicated on the top. The
different receptor chains and the major signaling pathways they trigger
are shown. The effect of each cytokine on NK cells is also mentioned at
the bottom.
IL-15
DISCOVERY/RECEPTORS/TRANS-PRESENTATION
IL-15 was discovered as a result of its “IL-2-like” stimulatory activ-
ity since it was able to support proliferation of IL-2 dependent cell
lines (14, 15). Structurally, IL-15 is a 14–15 kDa protein present-
ing sparse sequence similarity (19%) but extensive 3-dimensional
analogy with IL-2 and belonging to the same four α-helix bundle
cytokine family (15). IL-15 and IL-2 both interact with recep-
tor complexes containing the common gamma chain (γc) (16)
and IL-2/15Rβ chain (15, 17). The γc subunit also takes part
in the formation of the receptors for IL-4, IL-7, IL-9, and IL-21
(18) whereas IL-2/15Rβ is only used for signaling by IL-2 and
IL-15. IL-2 and IL-15 receptors only differ by their α chain, IL-
2Rα (CD25) being dedicated to IL-2 and IL-15Rα to IL-15 (19).
In contrast to IL-2Rα, IL-15Rα alone displays a high affinity of
binding for IL-15 (1.4× 10−11M), equivalent to that of the het-
erotrimeric IL-2R for IL-2 (19). This last property is fundamental
to understand the physiology of IL-15. Indeed, this high affinity,
coupled to the fact that IL-15 and IL-15Rα are co-expressed by the
same cells, allows intracellular binding of IL-15 to IL-15Rα in the
endoplasmic reticulum. The complex is then shuttled to the cell
membrane and presented to activate neighboring cells express-
ing IL-2/15Rβ/γc. This mechanism was called trans-presentation
(20, 21) and proposed to explain the counter-intuitive fact that
expression of IL-15Rα was not needed on responding NK cells to
maintain their homeostasis, as would have been expected for a clas-
sical cytokine response scheme, but on neighboring cells (22–26).
We can hypothesize that such a mechanism allows a very precise
delivery of the cytokine stimulus perhaps coupled to other stimu-
lating molecules. As NK cells rely on IL-15 for different purposes,
trans-presentation would confine IL-15 signal to selective niches
where it would sustain needs of specific NK cell sub-populations.
Moreover, systemic availability of this cytokine could be detrimen-
tal as exemplified by the development of fatal leukemia in IL-15
transgenic animals (27, 28). The debate whether cis-presentation
(i.e., autocrine presentation of IL-15) also occurs was recently
revived by a paper showing that following bacterial challenge, NK
cells produce and present IL-15 in a time frame and quantities
matching DCs and that this cis-presentation was as important as
DC trans-presentation to elicit NK cell IFN-γ production (29).
ROLE
The key role of IL-15 in NK cell biology is underlined by the com-
plete absence of these cells in mice deficient in components of the
IL-15 signaling axis (11, 12). However, the role of IL-15 in NK cell
physiology is not limited to development. Indeed, this cytokine
controls as well survival of mature NK cells in the periphery (24,
25, 30, 31), an effect that is probably mediated by up-regulation
of anti-apoptotic Bcl2 family members and down regulation of
apoptotic ones (31, 32). Moreover, resting NK cells are poor effec-
tors and need to be primed beforehand to express their full effector
capacity. This priming step is also controlled by IL-15, presented
by dendritic cells, or monocytes (33–38). Mechanistically, IL-15
signals NK cells to constitute stocks of the effector proteins GzmB
and Perforin, absent from unprimed NK cells (33). IL-15, syner-
gizing with IL-12, is also mandatory for IFN-γ expression by NK
cells (29, 34, 35). Finally, IL-15 controls NK cell homeostatic pro-
liferation (25, 36, 39) as well as proliferation induced following
bacterial, viral, or fungal infections (21, 35, 40, 41). How IL-
15 can mediate such a wide range of effects, some homeostatic
(differentiation, survival), and some context-dependent (priming,
IFN-γ secretion) is still unresolved. One possibility would be that
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varying IL-15 concentration triggers different responses on NK
cells. In line with this idea, decreasing γc expression levels results
in reduction of the peripheral NK cell pool (42, 43). This sug-
gests that maximal expression of this receptor and hence maximal
signal transduction is necessary for optimal transduction of the
IL-15 signal. A recent study tested this model in vivo using mouse
strains deficient for IL-15Rα or bearing chimeric IL-15Rα either
as transgene or knocked in the IL-15Rα locus (44). This strategy
allowed the authors to study NK cell populations exposed to five
different levels of IL-15 trans-presentation (from null to normal
levels). This disclosed the fact that on one hand, constituting a
normal peripheral NK cell pool, relying on high proliferation rate
in the BM, requires a high level of IL-15 trans-presentation. On the
other hand, maturation is much less demanding. The impact of
these different levels of IL-15 on the different signaling pathways
downstream of the IL-15R has not been analyzed.
REGULATION
How is IL-15 regulated at the basal state remains largely unknown.
IRF1, a transcription factor involved in type I IFN (IFN I)-induced
IL-15 production, probably plays a role in this process. Indeed,
expression of this factor is necessary on hematopoietic as well
as non-hematopoietic cells for NK cell generation (45). IL-15
mRNA is expressed in vivo by a number of tissues and cell types,
from hematopoietic (radiosensitive in chimera experiments) and
non-hematopoietic origin (radio-resistant) (24, 46, 47). Chimera
experiments have suggested that IL-15 trans-presentation by cells
of the hematopoietic system is the most efficient since limiting IL-
15Rα expression to the hematopoietic system is sufficient to gener-
ate normal NK cell numbers in the BM and only slightly decreased
numbers in the periphery (26, 39). In line with its dual function
in NK cell homeostasis and activation, IL-15 is expressed at low
level under homeostatic conditions in monocytes/macrophages
but this expression can be considerably enhanced by several pro-
inflammatory agents like LPS (48), poly(I:C), or IFN I (49). More
recently, using a transgenic mouse line in which emerald GFP
(EmGFP) is expressed under the control of endogenous Il15
regulatory elements, Lefrançois and collaborators have tracked
the cell subsets expressing IL-15 mRNA under homeostatic or
inflammatory conditions (50, 51). They confirmed the expres-
sion of this cytokine mRNA by a broad distribution of myeloid
cells including monocytes, neutrophils, eosinophils, mast cells,
and dendritic cells, the strongest expression being observed in
basophils. More surprisingly, they described high transcription
of IL-15 by Hematopoietic Stem Cells (HSC) and its progressive
down regulation during T cell differentiation (51). The signifi-
cance of this last result awaits further confirmation and functional
tests. In addition, IL-15 expression is regulated at several steps
including the post-transcriptional level. How much of this reg-
ulation is conserved in this reporter remains to be tested. It is
however worth noting that these results perfectly correlate with the
transcriptomic data available at the Immgen Consortium website
(www.immgen.org) for the cell types analyzed (52).
SIGNALING
In terms of signaling, most of our knowledge was generated by
studies focused on the IL-2-IL-2 receptor interaction (Figure 2).
FIGURE 2 | Signaling downstream IL-2/IL-15Rβ. Upon engagement of IL-2
or IL-15 different tyrosine residues are phosphorylated in the IL-2/15Rβ
intracytoplasmic regions, across two main regions (“A” and “H”). These
phosphorylations lead to the recruitment and downstream phosphorylation
of STAT5 by JAK1 and JAK3. The mTOR pathway takes also part to IL-15
signaling but the mode of mTOR activation is currently unknown. Activation
of mTOR is essential to increase NK cell metabolism. PI3K and MAPK are
also activated upon IL-2 engagement and probably also upon IL-15
engagement but this requires formal demonstration.
Given the shared receptor and the similarity of effect of IL-2 and
IL-15 on cultured cells, it was inferred that IL-15 stimulation would
lead to activation of the same pathways. And indeed, most of the
experiments conducted so far suggested a remarkable conserva-
tion. However, these two cytokines are not functionally redundant
as exemplified by the divergent immunological outcomes of IL-
2 or IL-15 treatment (53). A recent in vitro study aiming at
understanding these differences evidenced subtle changes in the
gene transcription induced in CD8 T cells stimulated with IL-2 or
IL-15 (54). This observation opens up the possibility that some
differences exist in the signaling pathways downstream of the IL-
2 or IL-15 receptors. In this context, the exact contribution of
the different signaling pathways during NK cell development and
activation is poorly understood. Upon IL-2 binding to its recep-
tor, signaling is triggered by Janus Kinases (Jak) 1 and 3, bound
to IL-15Rβ and γc (55–58). These kinases phosphorylate tyrosine
residues of IL-15Rβ, which serve as docking sites for phosphoty-
rosine binding proteins such as the Shc adapter protein, Insulin
Receptor Substrate (IRS) proteins, and STAT5a and b transcrip-
tion factors and lead to the activation of three main transduction
pathways: the Jak-STAT pathway, the phosphoinositide 3-kinase
(PI3K)/Akt pathway, and the Mitogen Activated Protein Kinase
(MAPK) pathway. Given its very proximal role in signal transduc-
tion, deficiency in Jak3 results in the absence of NK cells (59).
In an attempt to dissect the importance of the different path-
ways stemming from the IL-2/15Rβ subunit, complementation of
Il2/15rβ−/− mice with IL-2/15Rβ transgenes deleted for different
cytoplasmic domains was undertaken (60). This approach demon-
strated the necessity of the membrane distal H-region (Figure 2)
containing tyrosine 392 and 510 and known to recruit STAT3 and
5 and potentially the p85 subunit of PI3K for the generation of
a normal NK cell pool (60, 61). In contrast, the truncated pro-
tein generated after deletion of the membrane proximal A-region,
known to interact with Lck, the p85 subunit of PI3K and Shc, was
able to perfectly complement the IL-2/15Rβ deficient mice and to
restore NK cell homeostasis and functional response to IL-15 and
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seems thus dispensable. The importance of the STAT5 pathway
was confirmed by several studies (62, 63). Indeed, NK cell number
was reduced in STAT5b and to a lesser extend in STAT5a deficient
animals and this was associated with a decreased response to IL-2
and IL-15 (63). NK cell specific deletion of both STAT5 factors lead
to the complete disappearance of this population resulting from
survival defects, probably associated with a block of differentiation
at the NKP stage (62). In accordance with the putative role of the
H-region of IL-2/15Rβ to recruit p85 via phosphorylated Y392 is
a series of studies dissecting the role of the PI3K pathway in NK
cell development and functions (64–66). Class IA PI3Ks comprise
a p110 catalytic subunit associated with a p85, p55, or p50 regu-
latory subunit. The p110 catalytic subunits are encoded by three
genes Pik3ca, Pik3cb, and Pik3cd. Class IB PI3Ks consist of the cat-
alytic subunit p110γ (encoded by the Pik3cg ) associated with the
regulatory subunits p101 or p84. NK cells express all catalytic p110
(66), however only the role of p110γ and δ were examined using
mice deficient for these proteins (65, 66) or bearing a catalytically
inactive form of p110δ (64). Defect in p110γ or δ signaling lead to
a decrease in peripheral NK cell number (64–66), combined defect
in p110γ/δprevented terminal NK cell maturation (66). Moreover,
defect in PI3K signaling lead to impaired proliferative (64–66) and
cytotoxic (64, 66) responses to IL-2. Importantly, PI3K signaling
can be triggered by diverse stimuli including cytokines other than
IL-2 or IL-15 (67) chemokines (68) and NK activating receptors
(69). The phenotype described in the PI3K deficient NK cells can
thus be the consequence of the impairment of responses to other
stimuli and not only IL-15. Moreover, direct activation of PI3K
by IL-15 was not assessed in these studies neither in vitro nor
in vivo leaving the question of a direct effect unanswered. The
generation of phosphatidylinositol triphosphate by PI3K recruits
a vast number of targets to the plasma membrane and leads
to their activation. However, the downstream targets important
for NK cell differentiation and activation have not been investi-
gated. We recently discovered that the kinase mechanistic Target
Of Rapamycin (mTOR), which can be activated downstream of
PI3K, is a key signaling node activated by IL-15 and responsi-
ble for NK cell maturation and activation by pro-inflammatory
signals (Marçais et al. manuscript in preparation). mTOR is an
evolutionarily conserved serine/threonine kinase integrating var-
ious extracellular cues: metabolite and growth factors but also
antigenic and inflammatory signals as recently described for T cells
(70). mTOR takes part in two complexes: mTORC1 and mTORC2
differing by their constituting members and the targets they phos-
phorylate. We followed phosphorylation of key mTOR targets by
flow cytometry and showed that mTOR activity is developmen-
tally regulated with a progressive shut down upon differentiation
and BM egress. In contrast, mTOR activity is strongly induced
when NK cells are exposed to pro-inflammatory signals triggered
by poly(I:C) injection. Of note, mTOR activation necessitated high
IL-15 concentrations; instead, STAT5 phosphorylation was readily
triggered by low doses of IL-15. This could provide a first mol-
ecular basis to explain the dual effect of IL-15 on NK cells. We
also showed that IL-15 controls mTOR activity both in vitro and
in vivo. This is confirmed by the observation that NK cells har-
vested from mice with NK cell specific mTOR deletion are arrested
at the immature CD11blow CD27high stage and their activation in
response to poly(I:C) or IL-15 is severely impaired. Interestingly,
survival of mTOR deficient NK cells is not affected in accordance
with previous studies suggesting that the pro-survival signals given
by IL-15 are mediated by STAT5 (62). Preliminary results suggest
that only a fraction of mTOR activity is controlled via PI3K. This
would fit with the fact that the phenotype of mTOR deficient NK
cells is much stronger than PI3K deficient cells. The identity of the
relevant mTORC1 or mTORC2 downstream targets remains to be
addressed.
Apart from STAT5, the transcription factors, downstream of IL-
15 are not characterized. It is worth mentioning the fact that upon
MCMV infection, NK cells activate the E2F pathway, a phenom-
enon that can be blocked using blocking IL-2/15Rβ antibodies
(71). As IL-2 has been shown to mediate its proliferative effects
through E2F activation (72), we can hypothesize that E2F is also
involved in IL-15 induced proliferation. This has however not been
formally tested. Moreover IL-15 stimulation leads to NF-κB p65-
mediated increase in Myc expression in a context of IL-15 driven
leukemia (28).
IL-2
As discussed above, a number of IL-15 effects are recapitulated
by in vitro treatment with IL-2. In particular, it has long been
known that activated cytotoxic NK cells from BM culture can be
generated after exposure to IL-2 (73, 74). However, when IL-2
and IL-15 were compared, 10 to 50 times more IL-2 than IL-
15 was needed to activate NK cells (37). This is due to the fact
that NK cells do not express the high affinity IL-2 receptor due
to their lack of IL-2Rα expression at steady-state. Instead, trans-
presentation of IL-15 allows sensing of nanomolar quantities by
cells expressing only IL-2/15Rβ and γc (54). Whether IL-2 in vitro
effects are relevant in vivo is difficult to evaluate. Indeed, effect
on NK cells of mutations affecting IL-2 signaling are difficult to
interpret since they result in overt auto-immunity due to the role
of IL-2 in the generation and maintenance of Treg cells. To avoid
this caveat, mice deficient both for IL-2 and T cells have been gen-
erated. NK cell differentiation and numbers are normal in these
Rag−/− Il2−/− double deficient mice. IL-2 is thus not needed for
maintenance of NK cell homeostasis in the absence of T and B cells
(13). This is concordant with the fact that, unlike IL-15, which is
produced under homeostatic conditions, IL-2 production mainly
results from stimulation of the immune system. This cytokine
could nevertheless play a role during NK cell priming follow-
ing inflammatory challenge. Two studies even suggested that IL-2
could play a non-redundant role in this process (75, 76). Indeed,
Granucci et al. described a non-redundant role for IL-2 produced
by DCs in the first hours following bacterial challenge (76). In
this study, DC-derived IL-2 was important for the induction of
IFN-γ secretion by NK cells while induction of cytotoxicity was
independent of IL-2. A direct contact between the NK and the DC
was needed, suggesting that other molecules were involved. This
interaction was functionally relevant for bacterial clearance and
anti-tumor response. One caveat of this study is however the use
of IL-2 deficient DCs differentiated from BM harvested from IL-2
deficient hosts in which T cell dependent auto-immunity devel-
ops. Another study described that, following Leishmania major
infection, the T cell-derived IL-2 was necessary for the induction
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of IFN-γ secretion by NK cells (75). These findings are challenged
by the fact that NK cell priming does not happen in the absence
of IL-15 (29, 34, 35). A possibility to reconcile these studies would
be to imagine cooperation between the two cytokines, both being
needed. In this context, cytotoxicity induction would be under IL-
15 control specifically since IL-2 only impacts IFN-γ production in
these models (75, 76). The fact that 2 cytokines signaling through
the same IL-2Rβ/γc-STAT5-mTOR axis lead to such dissociated
effects could be due to difference in the spatio-temporal availabil-
ity as well as the mode of delivery of these cytokines to NK cells.
In any case, this issue remains open for further investigations.
Interest for the IL-2 dependent control of NK cells has recently
been renewed by a series of studies proposing that NK cell activity
was kept in check by Treg cells buffering excess IL-2 produced by
activated T cells (77,78). In these studies, the authors show that sys-
temic Treg cell depletion leads to an increase in CD4 T cell derived
IL-2. This increased IL-2 availability was correlated to increased
NK cell IFN-γ production (78) and cytotoxicity toward missing-
self targets (77) and could be abrogated by blocking IL-2 antibody
treatment. Similar findings have been reported upon transfer of
in vitro pre-activated NK cells in an irradiated host (79). Mecha-
nistically, Gasteiger et al. linked this increased responsiveness to a
better capacity to generate conjugates with target cells after even
very short-term exposure to IL-2. Interestingly, this increased cyto-
toxic capacity was only evidenced against missing-self targets, IL-2
being unable to increase cytotoxicity toward cells expressing both
inhibitory and activating ligands. The same group also described
phenotypical changes of the NK cell population with the pro-
gressive emergence of a CD127+ immature NK cell population
following Treg depletion (80). A similar population also accu-
mulated in tumor-bearing or chronically infected animals. This
population was able to up-regulate IL-2Rα upon low dose IL-12
stimulation confirming previous findings (81). The authors inter-
preted this result as an increase in the capacity to sense and use
IL-2. However, expression of IL-2Rα also renders cells more sensi-
tive to IL-15 (54), the cytokine involved in the homeostasis of this
population is thus debatable.
At this stage, we can conclude that DCs and monocytes prob-
ably have a prominent role in NK cell activation, through IL-15
trans-presentation. However, this does not exclude the fact that
other closely related cytokines like IL-2 and other cell types like T
cells or NK cells themselves can contribute and in some conditions
replace the IL-15 priming.
IL-21
IL-21R was discovered independently by two groups, it is homolog
to IL-2Rβ and its ligand, IL-21, homolog to IL-2, IL-4, and IL-15
with the strongest similarity with the latest (82, 83). Upon IL-
21 binding, IL-21R pairs with γc and signals through JAK1 and
STAT5 (82). IL-21 is expressed by activated CD4 T cells while IL-
21R is found on lymphoid cells (83, 84). Its first effects described
on human NK cells were a potentiation of differentiation from
BM progenitors and activation of mature NK cells (83). These
effects were in accordance with further studies showing that IL-
21 inhibits IL-15 effects on NK cell proliferation but potentiates
IL-15 driven NK cell terminal differentiation, i.e., cytotoxicity and
IFN-γ secretion (84–87). Forced expression of IL-21 in vivo by
hydrodynamic plasmid delivery decreases, in an NK cell depen-
dent manner, the number of lung metastasis obtained after tumor
cell lines injection (85). Given that IL-21 boosts T cell proliferation
in vitro, it was suggested that its production by activated T cells
could help shutdown the NK cell response once adaptive immunity
was functional (84). However no in vivo data came to confirm this
hypothesis. IL-21 produced by CD4 T cells is essential to prevent
CD8 T cell exhaustion during chronic viral infections (88–90). In
addition to direct positive effects on antiviral T cells, IL-21 restricts
virus-driven Treg cell expansion and their suppressive effect on
CD8 T cells (91). Whether IL-21 also controls the function of NK
cells during chronic infections remains to be formally tested even
though ex vivo treatment of NK cells from HIV-infected patients
with IL-21 improves their effector function (92, 93).
IL-7
IL-7, another member of the γc family of cytokines signaling via
STAT5, is well known for its role during early steps of B and T
cell development in the BM and thymus respectively (94). The fact
that early pre-pro NK cells and immature NK cells express high
levels of IL-7Rα (6) is puzzling since NK cell development and
acquisition of effector functions is perfectly normal in the absence
of IL-7 (13, 95). It should be noted that IL-7Rα is also used in
combination with the Cytokine Receptor-like factor 2 to form
the thymic stromal lymphopoietin receptor (TSLPR). Whether
this cytokine plays a role in early stages of NK cell physiology
is unknown. It has however been shown to regulate CD8 T cell
viability (96). A peculiar thymic IL-7-dependent NK cell subset
has also been described (97). This subset is present in minute
amount in mice thymi (between 10,000 and 100,000 cells), is vir-
tually absent in Il7−/− animals, expresses IL-7Rα and depends on
GATA-3 in contrast to BM derived NK cells. Functionally, these NK
cells are poorly cytolytic but secrete higher amount of cytokines
than conventional NK cells. Given the very low abundance of this
population, their function has not been investigated.
IL-4
IL-4 is also a member of the γc family of cytokines, well known
for its pro-Th2 effects during T cell differentiation. Its absence
does not affect NK cell generation and homeostasis (13). How-
ever, NK cells express the IL-4 receptor as evidenced by their
sensitivity to IL-4 treatment in vitro (86). Of note is the strong
ability of IL-4 to repress some key NK effector functions, such as
cytokine production or cytotoxicity. Indeed, it has been demon-
strated that IL-4 suppresses the inflammatory cytokine (IFN-γ,
TNFα, and GM-CSF) production-increase that is induced fol-
lowing IL-12 treatment in human NK cells (98). Similarly, in
mouse NK cells, IL-4 treatment induces a decrease in the cytokine-
induced-cytolytic-activity toward tumor cells or immature DC.
The mode of action of IL-4 did not involve a down regulation of
perforin or granzyme-B by NK cells but could be mediated through
NKG2D down regulation (86, 98). In line with these observations,
the capacity of NK cells to shape the adaptive immune response
and favor a polarized Th1 response through interactions with DCs
is abrogated when NK cells are pretreated with IL-4 (99). IL-4
treated NK cells are unable to induce DC maturation and favor
tolerogenic or Th2 responses (99).
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As mentioned above, another measurable effect of IL-4 was
to down regulate NKG2D and other NK cell markers expression
in vitro and in vivo and as a result to decrease NKG2D depen-
dent cell killing (86). Similarly IL-4 treatment has been shown to
down regulate NKG2D and CCL5 expression by memory CD8 T
cells (100–102). This is in contrast to the promotion, by IL-4, of
innate memory-like CD8 T cells generation that has been recently
described (103). In the mouse strain Balb/c, high frequency of
IL-4-secreting PLZF+ NKT cells is associated with increased pro-
portion of memory phenotype CD8 T cells compared to C57Bl/6
mice (104). The generation of this memory population has been
shown to be dependent on IL-4, as revealed by the lack of memory
phenotype CD8 T cells in Cd1d−/− and Il4r−/− mice. IL-4 pro-
duced during the course of a Th2 response is thought to act in a
similar way, as it induces a strong proliferation of memory pheno-
type as well as naive CD8 T cells (105). The stimulation of memory
CD8 T cells by IL-4 induces a strong up-regulation of the Eomes
transcription factor (104). Given the implication of Eomes in NK
cell differentiation, it is tempting to speculate that IL-4 could have
far reaching effects on NK cell biology.
IL-12 FAMILY
The IL-12 family of cytokines is constituted by heterodimeric
cytokines presenting a four α-helix bundle structure and belong-
ing to the IL-6 super-family (106). The constituting heterodimers
of this family are formed by combination of two possible β-chains
and three possible α-chains. Indeed, the cytokine β-chains are
components of two cytokines (p40 of IL-12 and IL-23 and Ebi3
of IL-27 and IL-35) while α-chains include p35, components of
IL-12 and IL-35, p19 component of IL-23, and p28 component of
IL-27. On the receptor side, IL-12 is recognized by an IL-12Rβ1/β2
receptor, IL-23 by an IL-12Rβ1/IL-23R heterodimer, IL-27 by an
IL-27R/gp130 complex, and IL-35 by a gp130/IL-12Rβ2. They have
activating as well as inhibitory roles on the immune system, IL-12
and IL-23 being seen as more pro-inflammatory while IL-27 and
IL-35 have been more described as inhibitory. Moreover, given the
receptors and ligands promiscuity, some members can compete
with others generating a complexity far from being understood.
IL-12
DISCOVERY/RECEPTORS
IL-12 was purified at the end of the 80s from the supernatant of
EBV immortalized B cell lines and named NK cell stimulating
factor (NKSF) for its ability to induce IFN-γ, cytotoxic activ-
ity, and proliferation of NK cells in vitro (107). NKSF was later
renamed IL-12 and is constituted of two polypeptides: IL-12p40
and p35 covalently linked by disulfide bonds, and binding to a het-
erodimeric receptor composed of IL-12Rβ1 and β2. Importantly,
NK cell constitutively express both chains of the IL-12R (108).
REGULATION/PRODUCTION
IL-12 is produced by several types of Antigen Presenting Cells,
including DCs (109, 110) and activated macrophages (48, 111).
In vivo, IL-12 is produced early after viral infection (112). The
inducing signals include pathogen derivative (113), sensed by TLRs
and the RIG I pathway, but also molecules expressed by activated
T cells like CD40L (109), or the NK cell derived IFN-γ (114–116).
The exact mechanism leading to IL-12 production can be more
complex as is the case following CpG stimulation. Indeed, upon
CpG injection in vivo, IL-12 is induced by IL-15 after a cross-talk
between conventional DCs and plasmacytoid DCs (117). Interest-
ingly, IL-12 delivery seems to involve the formation of a synapse
between the NK cell and the DC involving the polarization of the
DC’s secretory apparatus toward the NK cell (118).
SIGNALING
Upon binding, IL-12Rβ2 becomes tyrosine phosphorylated and
provides docking sites for the kinases tyk2 and Jak2 leading to the
phosphorylation and activation of STAT4 (119–121). The impor-
tance of tyk2 and STAT4 in NK cells is manifested by the sharp
decrease of IFN-γ production in mice deficient for these molecules
(40, 121). One report also suggests that some of IL-12 effects are
mediated by PKCθ (122), however no further study has confirmed
this point.
ROLE
The major role of IL-12 in vivo is to induce IFN-γ production,
while a marginal effect was described at first on early prolif-
eration and development of cytotoxicity (40, 112, 123). Indeed,
IFN-γ production is reduced 20-fold in IL-12p35 deficient mice
while cytotoxicity is intact (40), antibody mediated blocking of the
cytokine leads to similar results (112). Moreover, microscopy stud-
ies have shown a perfect time- and location-dependent correlation
between IL-12 production by DCs and IFN-γ production by NK
cells in Listeria induced granuloma (124). As IFN-γ can itself pro-
mote IL-12p40 expression, it generates a positive feedback loop
promoting inflammation and the differentiation of monocytes
into DCs (114, 124). More recently, it has been shown that IL-12 in
combination with another cytokine, IL-18, helps optimal NK cell
expansion (125, 126) an effect which is not dependent on IFN-γ
secretion. Moreover, in some settings, IL-12/IL-18 can drive an
IL-15 independent response of NK cells (127, 128). However these
results are controversial, indeed, another study found no or only a
very minor role of IL-18 and IL-12 for the promotion of the expan-
sion of Ly49H+ NK cells during MCMV infection in vivo (129).
Moreover, the settings used in one study are very peculiar since they
involve adoptive transfer of WT NK cells in Il15−/−× Il15rα−/−
mice to unmask the IL-12 dependent proliferative effects (128).
At the molecular level, induction of IFN-γ by IL-12 secretion
relies on increased transcription as determined by run-on exper-
iments (130). This transcriptional response is abrogated in tyk2
deficient mice (121). IFN-γmRNA, like many other cytokine mes-
sengers, bears AU rich elements in its 3′UTR, which renders it
unstable (131) moreover, it is also a target for miRNA mediated
regulation (132). Hence, a large part of its expression relies on
post-transcriptional regulation. In this context, it has been shown
that IL-18 stabilizes the IFN-γ mRNA through the activation of
a MAPK p38 dependent pathway (133) (Figure 3). This effect
explains at least in part the formidable synergy existing between
IL-12 and IL-18 on induction of IFN-γ secretion (134). Inter-
estingly, IL-12 in combination with IL-18 can also trigger IFN-γ
secretion by memory T cells in vivo in an antigen independent
fashion underlying acquisition of “innate-like” capacities by these
cells (38, 135). Conversely, several groups have been able to induce
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FIGURE 3 | Synergy between IL-12 and IL-18 for the induction of IFN-γ
production. Engagement of the heterodimeric IL-12 receptor leads to STAT4
phosphorylation after recruitment of the kinases Tyk2 and JAK2. STAT4
transctivates IFN-γ transcription. Upon binding of IL-18 to its receptors there is
activation of the MAPK pathway downstream the adapter MyD88. This leads
to the stabilization of IFN-γ mRNA and enhances IFN-γ secretion by NK cells.
Other mechanisms may also contribute to the synergy between IL-12 and
IL-18.
long-term survival of an NK cell population by transferring NK
cells briefly activated in vitro in the presence of IL-12 and IL-18
in sublethally irradiated (79) or Rag−/− hosts (136). This echoes
the concept of NK cell memory proposed in 2006 by the group
of von Andrian (137). Indeed, under particular circumstances,
a fraction of the activated NK pool survives the resolution of the
response and is able to mount recall responses (126). This property
is severely impaired in the absence of IL-12 (126). How exposure
to these cytokines imprints long-term survival onto NK cells in
these particular settings is not understood and could constitute
fertile ground for further discoveries.
As previously mentioned, IL-12, in synergy with IL-18, has the
capacity to induce IL-2Rα on NK cells (81, 86), the CD127+ popu-
lation of NK cells being extremely sensitive to this stimulation (80).
This property may help to explain the sustained IL-2-dependent
proliferation of IL-15/IL-12/IL-18 pre-activated NK cells after
in vivo transfer (79). IL-18 is not the only cytokine synergizing
with IL-12. Indeed, early studies described a synergy between IL-
12 and IL-2 (107). Similarly to IL-18, the synergy between IL-12
and IL-2 also involves regulation of IFN-γ mRNA half-life (130).
IL-18
IL-18 is a cytokine that was originally identified as an IFN-γ
inducible factor (IGIF) (138) and it appears to share its biologic
functions with IL-12, including enhancement of the NK cell activ-
ity (139). Its absence leads to decreased NK cell response in a
variety of models (140, 141). It is part of the IL-1 family which
comprises 11 members (142). It is produced as an inactive pro-
IL-18 precursor. In contrast to other IL-1 family member such as
IL-1β,proIL-18 is constitutively expressed (143). ProIL-18 requires
cleavage by active caspase-1 in the inflammasome complex to
generate biologically active IL-18 (144, 145). Other proteases
[caspase-8 (146, 147), proteinase-3 (148), granzyme-B (149)] have
been reported to cleave proIL-18 and generate bioactive cytokine.
The physiologic producers of IL-18 include myeloid cells such
as activated macrophages (138, 150), dendritic cells (151), neu-
trophils (152), and Ly6C+CCR2+ inflammatory monocytes (38).
In addition, IL-18 is expressed in numerous non-hematopoietic
lineages (153). IL-18 mature form is a leaderless protein secreted
via a poorly understood mechanism (154). The ability of IL-18
released by macrophages or DCs to activate the production of IFN-
γ by NK cells is dependent on cell-to-cell contact (155–159). In
agreement with this cell-to-cell contact requirement, IL-18 secre-
tion by DC is polarized and occurs at the immunological synapse
formed between the DC and the NK cell (160). Furthermore,
another regulatory step may include the presence of a membrane-
bound form of IL-18 as an intermediate between the cytosolic pro
IL-18 and the mature soluble IL-18 (161). Finally, IL-18 signal-
ing can be antagonized by IL-18BP, which is limiting the systemic
effects of this cytokine (162).
Upon IL-18 binding, its primary receptor, IL-18R1, dimer-
izes with a second receptor subunit: IL-18R accessory pro-
tein (IL-18RAP). This recruits myeloid differentiation primary
response protein 88 (MyD88) and initiates signaling through IL-
1R-associated kinase 4 (IRAK4) and TNFR-associated factor 6
(TRAF6), leading to activation of the NF-κB and MAPK pathways.
The importance of IL-18 for NK cells is underlined by the fact that
at steady state, NK cells are the only hematopoietic cells analyzed
by the Immunological Genome Project to contain consequent lev-
els of transcripts for IL-18R1 and IL-18RAP (www.immgen.org).
This expression grants them with exquisite sensitivity to IL-18
stimulation (150). Moreover, NK from IL-18R1-deficient mice
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have decreased IFN-γ secretion and cytotoxic capacities (163). A
similar phenotype is observed in IRAK4 deficient NK cells (164).
Other pathways may also be activated as suggested by impaired
IFN-γ secretion in response to IL-12/18 stimulation in p110γ or δ
deficient NK cells (65, 66). IL-18 is critical for IFN-γ production by
NK cells during numerous bacterial (165), fungal (166), parasites
(127), and viral (167) infections. In addition to regulating IFN-γ
production, IL-18 takes part to the priming of NK cells (29, 168),
and leads to the acquisition of novel migratory function through
up-regulation of CCR7 (155, 169). It has also been shown that
IL-18 induces the release of CC chemokine Ligand 3 (CCL3) by
NK cells, which in turns recruits inflammatory monocytes in the
intestine and contribute to local inflammation (170).
The role of IL-18 in regulating the anti-tumoral activity of NK
cells is unclear and might be highly dependent of the other sig-
nals received by NK cells concomitantly to IL-18. Indeed IL-18 has
been shown to promote tumor immuno-suppression and tumor
growth by converting Kit− NK cells into Kit+ NK cells. NK cells
from this Kit+ subset have the potential to lyse DCs leading to a
reduction in the tumor immuno-surveillance (171). In contrast,
others studies have demonstrated an anti-tumor effect of IL-18
(172, 173) in part through the generation of “helper” NK cells
producing CCL3 and CCL4, which results to the local recruitment
of DCs and effector CD8 T cells (174).
As detailed above, the main effect of IL-18 on NK cells is to syn-
ergize with IL-12 to induce IFN-γ production. However, in some
systems, IL-12 can be dispensable while IL-18 is not (29, 175).
Importantly, if systemic IFN-γ production depends on IL-12/IL-
18 synergy, local IFN-γ production in the liver can be preserved in
the absence of IL-18 and be sufficient to allow host survival upon
MCMV infection (167).
TRANSFORMING GROWTH FACTOR-β
PRODUCTION
Transforming growth factor-β is a cytokine with a pivotal role in
the regulation of the immune system. TGFβ1 is the predominant
TGFβ isoform expressed in the immune system. TGFβ associates
non-covalently with the latency-associated protein (LAP), form-
ing a complex called the small latent complex (SLC). The SLC can
be secreted as such or in association with latent TGFβ-binding
protein (LTBP) as a large latent complex (LLC). TGFβ must be
released from the complexes to bind to TGFβ receptors (176). This
can be achieved through different mechanisms that remain mostly
unclear. TGFβ binding proteins control ligand access but can also
act as ligand reservoirs (177). Virtually all cells of the immune
system can produce TGFβ. TGFβ is regulated at transcriptional,
post-transcriptional, and post-translational levels. It is therefore
difficult to precisely determine the sources of active TGFβ during
immune responses.
SIGNALING
Transforming growth factor-β mediates its biological functions
through binding to type I and II transmembrane serine/threonine
kinase receptors. TGFβ1 signals mostly via TGFBR1 (type I recep-
tor) and TGFBR2 (type II receptor). TGFBR1 is not necessary
for binding to TGFβ but initiates signaling. Two signaling path-
ways have been described that are dependent or not on smad
transcription factors. Receptor-associated smads (mostly R-smad
2 and 3 in the immune system) are sequestered in the cytoplasm
in the absence of signaling. Upon phosphorylation by TGFBR1,
R-smad 2 and 3 interact with the common mediator smad-4 and
are translocated into the nucleus. Smad complexes recruit other
transcription factors to activate or repress the expression of a
wide range of genes. Various Smad-independent TGFβ signaling
pathways operate in a context-dependent manner and contribute
to cell-specific biological responses. TGFβmay thus activate small
GTPases, MAP kinases, and the PI3K pathway (177). In T cells,
a JNK-c-Jun pathway has been shown to suppress the expres-
sion of Eomes in Th17 cells in response to TGFβ (178). In NK
cells, smad-independent TGFβ signaling pathways have not been
addressed.
IMPACT OF TGFβ ON NK CELLS
The addition of recombinant TGFβ in cultures of mouse spleen
cells or human PBMC with IL-2 in vitro has long been shown to
reduce NK cell proliferation and cytotoxicity (179–182). Adminis-
tration of TGFβ also depresses NK cell activity in mice (183), and
reduces their proliferation during antiviral responses (184) while
blocking TGFβ increases NK cell cytotoxic activity (185). It was
later found that TGFβ also counteracts IL-12 mediated cytokine
production by mouse NK cells (186, 187) and human NK cells
(188, 189). TGFβ not only counteracts the effects of IL-2 and IL-12
but also reduces IFN-γ production in response to the engagement
of the Fc receptor CD16 on human NK cells (190). Finally, TGFβ
also shapes the NK cell surface by reducing the expression of NK
cell receptors NKG2D and NKp30 (191, 192) and changes their
trafficking properties by modulating the expression of chemokine
receptors (193).
When does TGFβ act on NK cells in vivo? Early studies show
that TGFβ is produced during viral infections, especially by T
cells at late stages of infection, which could help limiting NK
cell cytotoxicity (194). More recent studies show that the trans-
genic expression of a dominant negative form of the TGFBR2
receptor in CD11c positive cells (including dendritic cells and NK
cells) dramatically increases the number of mature NK cells (195),
suggesting that TGFβ negatively regulates NK cell development
and maturation at steady-state, especially during infancy (196).
The smad-dependent pathway has been shown to be important
to limit NK cell IFN-γ production by repressing the expression of
T-bet (189). Whether this pathway also limits NK cell proliferation
and cytotoxicity induced by pro-inflammatory cytokines remains
to be determined. Early studies have suggested that TGFβ acts
very rapidly, perhaps in a smad3 independent manner to decrease
tyrosine phosphorylation induced by IL-2 (197).
IL-10
IL-10 was described as a Th2 cytokine that inhibited Th1 cytokine
synthesis (198). It is now known to be produced by macrophages,
DCs, B cells, various subsets of T cells, and NK cells themselves
(199–202). NK cells constitutively express both chains of IL-10
receptor (Immgen data). Several diverging effects of IL-10 on NK
cells have been described (203–207). Most of these effects seem to
be indirect, indeed, IL-10 in vitro treatment of purified NK cells
does not have noticeable effects (86). However, to the best of our
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knowledge, this has not been thoroughly tested using chimeras or
transfer of IL-10R deficient or sufficient NK cells in IL-10 suffi-
cient hosts. The experiments of in vivo blockade using antibodies
being non-informative about the responding cell type (208, 209).
IFN I
IFN-α/β or type I IFN (IFN I) were originally identified as proteins
responsible for induction of cellular resistance to viral infections.
They are produced by various immune and non-immune cell
types. According to a recent study, the capacity of mononuclear
phagocytes (i.e., DCs and macrophages) to express IFN I and sub-
sequently IL-15 after microbial challenge could be imprinted by
previous contact with the microbial flora (210). However this
results still awaits confirmation. IFN I effects on NK cells have
been known for a long time. Indeed, IFN I induce NK cell prolif-
eration and cytotoxicity (211). However, IFN I receptor (IFNAR)
deficiency can be compensated by recombinant IL-15 injection
(40). The bulk of IFN I effects are thus probably mediated through
release of IL-15 as recently confirmed by a systems biology analy-
sis of the response to MCMV viral infection (71). In this study,
the authors show that IFN-stimulated genes were not strongly
up regulated by NK cells, suggesting that, at least at the tran-
scriptional level, these cells were not the primary targets of IFN
I. This lower responsiveness was associated with a lower expres-
sion of STAT1 by NK cells. IFN I dependent effects on NK cells
are however not absent and some studies have evidenced a direct
role of IFN I on the induction of NK cell cytotoxicity (212,
213).
CONCLUDING REMARKS
Natural killer cell development and function depend on a multi-
plicity of cytokines which have complementary as well as over-
lapping functions. A complete understanding of their action
will require the precise identification of the cell types produc-
ing them, the time window during which they are produced
and the signaling events that their receptors engage in NK cells.
These various parameters and the outcome on NK cells could
be very different depending on the infectious agent. The role
of some cytokines such as IL-2 may thus be important only
with particular pathogens and efforts should therefore be made
to diversify the models of infection. Moreover, many cytokine
effects are only seen when combining them, as best exempli-
fied by IL-12 and IL-18. It is therefore essential to define the
relevant cytokine combinations in different niches and to delin-
eate the signaling pathways they induce as well as their com-
bined effects on NK cells. How NK cells integrate signals from
activating and inhibitory cytokines and which molecules act as
“integrators” are important issues to address. Recent technolog-
ical advances such as mass cytometry will be instrumental for
this purpose in that they allow the simultaneous measurement
of up to 100 parameters using very low cell numbers. The lat-
ter technique can be applied to the study of cell signaling using
phospho-specific antibodies raised against various molecules of
the transduction machinery. Recently generated NK-specific Cre-
expressing mouse lines will also be important to discriminate
between direct vs. indirect effects of various cytokines on in vivo
NK cell physiology.
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